Elicio Therapeutics, Inc. — Director's Dealing 2025

May 20, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Elicio Therapeutics, Inc. (ELTX)
CIK: 0001601485
Period of Report: 2025-05-19

Reporting Person: Ashe Carol Gail (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-05-19	Stock Option (Right to Buy)	$5.84	A	7900	Acquired	2035-05-19	Common Stock (7900)	Direct

Footnotes

F1: The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after
the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.